1）Yorozu A, Kuroiwa N, Takahashi A, et al：Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan：Outcomes of 1300 patients. Brachytherapy, in press, 2014
2）Tanaka N, Asakawa I, Katayama E, et al：The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions. Radiat Oncol 9：107, 2014
3）Yamada Y, Masui K, Iwata T, et al：Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men：Outcome and toxicity. Brachytherapy, in press, 2014
4）National Comprehensive Cancer Network（NCCN）：Clinical Practice Guidelines in Oncology, Prostate Cancer. http://www.nccn.org
5）Gleave ME, Goldenberg SL, Chin JL, et al：Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy：biochemical and pathological effects. J Urol 166：500-506, 2001
6）Eri LM1 and Tveter KJ：A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 150：359-364, 1993
7）Eri LM and Tveter KJ：A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Urol 150：90-94, 1993
8）Merrick GS, Butler WM, Wallner KE, et al：Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology 68：116-120, 2006
9）Bolla M, Van Tienhoven G, Warde P, et al：External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk：10-year results of an EORTC randomised study. Lancet Oncol 11：1066-1073, 2010
10）Bolla M, de Reijke TM, Van Tienhoven G, et al：Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360：2516-2527, 2009
11）Pilepich MV, Winter K, Lawton CA, et al：Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase Ⅲ RTOG 85-31. Int J Radiat Oncol Biol Phys 61：1285-1290, 2005
12）Jones CU, Hunt D, McGowan DG, et al：Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365：107-118, 2011
13）Merrick GS, Butler WM, Wallner KE, et al：Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65：669-677, 2006
14）Stone NN and Stock RG：15-year cause specific and all-cause survival following brachytherapy for prostate cancer：negative impact of long-term hormonal therapy. J Urol 192：754-759, 2014
15）Zelefsky MJ, Chou JF, Pei X, et al：Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer：The Memorial Sloan-Kettering Cancer Center experience. Brachytherapy 11：245-245, 2012
16）Stock RG, Buckstein M, Liu JT, et al：The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes. BJU Int 112：E44-50, 2013
17）Marshall RA, Buckstein M, Stone NN, et al：Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer：20-year experience at Mount Sinai Medical Center. Urol Oncol 32：38, 2014
18）Miki K, Kiba T, Sasaki H, et al：Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer：study protocol for a phase Ⅲ, multicenter, randomized, controlled trial. BMC Cancer 10：572, 2010
19）Konaka H, Egawa S, Saito S, et al：Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer（TRIP）：study protocol for a phase Ⅲ, multicenter, randomized, controlled trial. BMC Cancer 12：110, 2012
ログイン
ランキング
お知らせ
ログイン
